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Background: Limited data suggest that patients with atrial fibrillation (AF) often have - gastrointestinal (GI) comorbid conditions. However, many 
medications used in AF management may increase the risk of GI events. This analysis was performed to describe the prevalence and cumulative 
incidence of GI events among AF patients. 
Methods: Healthcare claims from the Thomson Reuters MarketScan® database were analyzed from 01/2005-12/2009, all subjects aged ≥18 
years as of the date of first AF diagnosis, with ≥180 days of continuous insurance coverage prior to the index AF, were selected. GI events were 
identified from claims with a primary or secondary diagnosis code for any GI condition. The subset of GI conditions analyzed included dyspepsia 
(upper abdominal pain, abdominal pain, abdominal discomfort, and dyspepsia), diarrhea, vomiting, and GI bleeding. The risk of new GI events was 
assessed among patients with AF without GI condition at baseline. Incidence rates (IRs) of GI events were calculated as the number of patients with 
an event divided by patient-years of observation. 
Results: A total of 557,123 AF patients were identified, of whom 143,955 (26%) had a GI condition recorded during the 180-day baseline period 
prior to the index AF. The mean age of AF patients was 68 years (median; SD) (70; 15); 45% were female. Over the study period (180-day baseline 
and mean follow-up of 543 days), 308,823 (55%) AF patients had ≥1 GI event. Dyspepsia, occurring in 30%, was the most common GI event. 
Other conditions included diarrhea (8%), vomiting (8%), and GI bleeding (10%). The incidence of any GI event and dyspepsia were 40% and 19%, 
respectively. The corresponding IRs were 38.8 and 14.7 events per 100 patient-years, respectively. During the baseline period, 359,398 patients 
(65%) had ≥1 medication dispensed which had the potential to cause GI tolerability issues. 
Conclusions: In this large claims database, AF was associated with a 40% risk of developing a GI event. This rate of GI events may affect 
medication adherence in AF patients and may be a significant contributor to nonadherence to AF therapy. Our data suggest that prescribers should 
carefully consider the baseline GI disease burden in the AF population.
